CD147/EMMPRIN and CD44 are Potential Therapeutic Targets for Metastatic Prostate Cancer
Journal:
Current Cancer Drug Targets
Volume:
10
Page:
287-306
Author(s):
J.L. Hao, P.J. Cozzi, A. Khatri, C.A. Power and Y. Li
MicroRNAs in Cancer Therapy: From Bench to Bedside
Journal:
Current Cancer Therapy Reviews
Volume:
6
Page:
157-162
Author(s):
Srikumar Sengupta and Anupam Bishayee
Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia
Journal:
Current Drug Safety
Volume:
5
Page:
171-181
Author(s):
Adam Cuker, Elaine Y. Chiang and Douglas B. Cines
Cell Cycle as a Target of Antineoplastic Drugs
Journal:
Current Pharmaceutical Design
Volume:
16
Page:
1417-1426
Author(s):
Maria De Falco and Antonio De Luca
Adverse Effects and Drug Interactions of Biologic Agents
Journal:
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Volume:
9
Page:
46-53
Author(s):
Yasemin Turan
Future Prospect of RNA Interference for Cancer Therapies
Journal:
Current Drug Targets
Volume:
11
Page:
345-360
Author(s):
Eishi Ashihara, Eri Kawata and Taira Maekawa
Silibinin – A Promising New Treatment for Cancer
Journal:
Anti-Cancer Agents in Medicinal Chemistry
Volume:
10
Page:
186-195
Author(s):
Catherine Wing Ying Cheung, Norma Gibbons, David Wayne Johnson and David Lawrence Nicol
Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Journal:
Current Pharmaceutical Design
Volume:
16
Page:
1040-1054
Author(s):
Kathlynn C. Brown
Toll-Like Receptors: Cost or Benefit for Cancer?
Journal:
Current Pharmaceutical Design
Volume:
16
Page:
1081-1090
Author(s):
T. Matijevic and J. Pavelic
Antitumor Effect of Butanoylated Heparin with Low Anticoagulant Activity on Lung Cancer Growth in Mice and Rats
Journal:
Current Cancer Drug Targets
Volume:
10
Page:
229-241
Author(s):
Lunyin Yu, Hari G. Garg, Boyangzi Li, Robert J. Linhardt and Charles A. Hales